, the leading manufacturer of vaccines in America, has submitted a bid to the Food and Drug Administration () to begin distributing booster shots for children aged five to 11. The New York City-based company made the announcement Tuesday afternoon, also revealing results of its Phase 2/3 clinical trials which raised Covid antibody levels in the age group 36-fold without any serious complications.If approved, it would be the first booster dose available to the age group, as the Pfizer-BioNTech shot is the only one available to Americans under the age of 18.
Load More
Load More